Last reviewed · How we verify
Low dose losartan
Low dose losartan is a Angiotensin II receptor blocker (ARB) Small molecule drug developed by Baker Heart and Diabetes Institute. It is currently FDA-approved for Hypertension, Heart failure, Diabetic nephropathy. Also known as: losartan (Cozaar).
Low-dose losartan blocks angiotensin II type 1 receptors to reduce blood pressure and improve cardiovascular outcomes.
Low-dose losartan blocks angiotensin II type 1 receptors to reduce blood pressure and improve cardiovascular outcomes. Used for Hypertension, Heart failure, Diabetic nephropathy.
At a glance
| Generic name | Low dose losartan |
|---|---|
| Also known as | losartan (Cozaar) |
| Sponsor | Baker Heart and Diabetes Institute |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Losartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, preventing angiotensin II-mediated vasoconstriction and aldosterone release. At low doses, it provides cardiovascular protection with potentially improved tolerability compared to standard doses, particularly in heart failure and hypertension management.
Approved indications
- Hypertension
- Heart failure
- Diabetic nephropathy
Common side effects
- Hyperkalemia
- Dizziness
- Fatigue
- Hypotension
- Cough
Key clinical trials
- Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients (EARLY_PHASE1)
- An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension (PHASE3)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study (PHASE2)
- Multidiscipline Care for Acute Kidney Disease (AKD) (NA)
- A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension (PHASE2)
- Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study (PHASE4)
- Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low dose losartan CI brief — competitive landscape report
- Low dose losartan updates RSS · CI watch RSS
- Baker Heart and Diabetes Institute portfolio CI
Frequently asked questions about Low dose losartan
What is Low dose losartan?
How does Low dose losartan work?
What is Low dose losartan used for?
Who makes Low dose losartan?
Is Low dose losartan also known as anything else?
What drug class is Low dose losartan in?
What development phase is Low dose losartan in?
What are the side effects of Low dose losartan?
What does Low dose losartan target?
Related
- Drug class: All Angiotensin II receptor blocker (ARB) drugs
- Target: All drugs targeting AT1 receptor (Angiotensin II type 1 receptor)
- Manufacturer: Baker Heart and Diabetes Institute — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Heart failure
- Indication: Drugs for Diabetic nephropathy
- Also known as: losartan (Cozaar)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing